The Millennium Problems for Biology
The cell entry mechanism must be plausible in a therapeutic context, i.e., transfection, intrabody expression, electroporation, membrane disruption, or similar methods are not permitted. The challenge will be considered complete when the design can be demonstrated against 20 preregistered targets with an 80% success rate. However, it is anticipated that modifications to the antibody scaffold will be required in order for the problem to be solvable.
- ▪The cell entry mechanism must be plausible in a therapeutic context, i.e., transfection, intrabody expression, electroporation, membrane disruption, or similar methods are not permitted.
- ▪The challenge will be considered complete when the design can be demonstrated against 20 preregistered targets with an 80% success rate.
- ▪However, it is anticipated that modifications to the antibody scaffold will be required in order for the problem to be solvable.
Hacker News (Front Page) files mainly under programming. We currently carry 1,885 of its stories. Top-voted stories on Hacker News.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Hacker News (Front Page) |
| Canonical URL | https://millenniumproblems.bio/ |
| Publication time | Sun, 20 Sep 2026 12:17:54 +0000 |
| Retrieval time | 2026-09-20T13:08:46.573Z |
| Last seen | 2026-09-20T13:08:46.573Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | MWQ7GkPlKvk3 · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Demonstrate the ability to produce protein binders against intracellular targets.Specifically, demonstrate the ability to design zero-shot protein binders that, without further evolution or optimization, will reliably engage preregistered intracellular protein targets in living cells when administered extracellularly to those cells at pharmacologically supported concentrations. The cell entry mechanism must be plausible in a therapeutic context, i.e., transfection, intrabody expression, electroporation, membrane disruption, or similar methods are not permitted. The challenge will be considered complete when the design can be demonstrated against 20 preregistered targets with an 80% success rate.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Hacker News (Front Page).
Discussion
0 commentsMore from Hacker News (Front Page)
